Anyone has treatment addressing Genomic ATM Mutations?

[Shorehousejam]

I have a tier 1 genomic mutation

ATM FRAMESHIFT MUTATION

Anyone try Provenge?

I am trying to found if

I should do the drug of the moment suggested to me Keytruda by MSK

ARK Inhibitors

A Vaccine maybe?

I’m in chemotherapy for Liver Mets see bio

MSK wants to add Keytruda

He said all parp inhibitors are basically the same

Please share your experience

[StayingOptimistic]

if I was you, I would listen to the MSK MO.

[Shorehousejam in reply to StayingOptimistic]

I plan too, just want to explore all possible options and make the best decision

I just wish someone here can share experiences with atm mutations

[StayingOptimistic in reply to Shorehousejam]

Try asking TALL_Allen. he knows.

[Shorehousejam in reply to StayingOptimistic]

I did, he said it doesn’t work on ATM Mutations but I also read studies some people do have a response

[Shorehousejam]

Absolutely I am just afraid of it all going haywire

[God_Loves_Me]

agree with comments, listen to doctor

I am Not doctor it’s not advice just trying to put something that may help you. Tell your MO to send your biopsy tissue to Keytruda and they can tell immediately

I was reading on internet and one user mentioned that his MO did this and worked very well

[Shorehousejam in reply to God_Loves_Me]

I will definitely asked great advice

[Shorehousejam]

Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is administered by slow intravenous injection.

I keep forgetting it’s Not parp inhibitor

[Shorehousejam]

These are some PARP inhibitors:

Olaparib (Lynparza)

The most widely used PARP inhibitor

Niraparib (Zejula)

A PARP inhibitor approved to treat ovarian, breast, pancreatic, and/or prostate cancer

Rucaparib (Rubraca)

A PARP inhibitor approved to treat ovarian, fallopian tube, peritoneal, and prostate cancer

Talazoparib (Talzenna)

A PARP inhibitor approved to treat ovarian, breast, pancreatic, and/or prostate cancer

[j-o-h-n in reply to Shorehousejam]

Sorry if I'm repeating myself. Keytruda (at MSK) worked for my Melanoma which metastasized to my Lungs. (Not related to my Pca).

Good Luck, Good Health and Good Humor.

j-o-h-n

[Boywonder56]

my son thinks im a ATM mutation.....

[j-o-h-n in reply to Boywonder56]

You're not?

Good Luck, Good Health and Good Humor.

j-o-h-n

[StayingOptimistic]

fyi..

healthunlocked.com/advanced...

[KocoPr]

as ahk1 posted above on a new post from Maxone73

His quote “as I reported, one of the patients on the trial (with ATM mutation) had a 100% remission..”

[Maxone73 in reply to KocoPr]

yes, temporary, I mean, I do not know how he is now after 7 months but the PSA drop was dramatic

[KocoPr]

Anything to fight ATM is a plus

[KocoPr]

aacrjournals.org/clincancer...

Conclusions:

AZD5305 potently and selectively inhibits PARP1 resulting in excellent antiproliferative activity and unprecedented selectivity for DNA repair deficient versus proficient cells. These data confirm the hypothesis that targeting only PARP1 can retain the therapeutic benefit of nonselective PARPi, while reducing potential for hematotoxicity. AZD5305 is currently in phase I trials (NCT04644068).

Translational Relevance

Here we describe the primary pharmacology of a next-generation PARP inhibitor (PARPi) and trapper, AZD5305, designed to address the limitations of current clinical PARPi, particularly in combination with first-line chemotherapy. In biochemical and cellular assays, AZD5305 shows high selectivity for PARP1 versus other PARP family enzymes. In multiple in vivo models, AZD5305 shows robust anticancer efficacy both as monotherapy and in combination. In rat preclinical toxicology models, AZD5305 causes minimal hematologic toxicity as monotherapy and is differentiated from first-generation PARPi in combination. Overall, AZD5305 demonstrates that potent and selective inhibition and trapping of PARP1 represents a promising avenue to achieve improved outcomes for patients treated with PARPi.

[Shorehousejam in reply to KocoPr]

Thank you